<DOC>
	<DOCNO>NCT02910375</DOCNO>
	<brief_summary>This retrospective multi-centric Belgian prospective trial involve 10 patient initiate maintenance subcutaneous golimumab therapy moderate-to-severe colitis University Hospitals Leuven ( Leuven , Belgium ) AZ Groeninge ( Kortrijk , Belgium ) Patients ( ) receive ( ) standard induction therapy golimumab 200mg week 0 , golimumab 100mg week 2 . Maintenance therapy ( ) start ( ed ) week 6 , 50 100mg golimumab every 4 week , depend body weight ( 50mg every 4 week patient body weight less 80kg , 100mg others ) Patients come hospital clinical evaluation , blood sample golimumab administration follow daily clinical practice . The patient request perform several dry blood spot analyse home .</brief_summary>
	<brief_title>Golimumab Dried Blood Spot Analysis</brief_title>
	<detailed_description>BLOOD SAMPLING : Blood sample collect use two sample method different time point ( indicated timeline ) ; DBS sampling ( max 39 samples/patient ) venous blood sampling ( max 13 samples/patient ) . Venous blood sample perform standard outpatient clinic one participating centre , forward Laboratory Therapeutic Diagnostic Antibodies Leuven analyse . DBS sample send directly Laboratory Therapeutic Diagnostic Antibodies Leuven classical mailing . DBS sample perform patient outpatient clinic ( moment venous puncture , max 13 samples/patient ) home intermediate value ( max 26 samples/patient ) . Patients teach perform finger prick outpatient clinic . A conversion factor define . Determination concentration-time profile exposure golimumab individual patient perform intensive sample 3 4.5 month . Time point max concentration , intermediate concentration , trough concentration determine patient . Note : A similar procedure adopt measure free anti-golimumab antibody concentration DBS use drug sensitive assay . Free anti-golimumab antibody concentration measure serum golimumab concentration limit quantification . MEASUREMENT OF GOLIMUMAB AND ANTI-GOLIMUMAB ANTIBODY CONCENTRATIONS : Golimumab concentration measure use sandwich type ELISA , golimumab capture immobilized monoclonal antibody towards golimumab ( MA-GLM ) 171D8 add horseradish peroxidase ( HRP ) -labeled MA-GLM159B8 . The assay develop validate , analytically ( external internal ) clinically , describe Detrez et al . Golimumab concentration measure every sample . Free anti-golimumab antibody concentration measure use drug sensitive assay . Total anti-golimumab antibody concentration measure use drug tolerant assay . Development validation ( analytical + clinical ) assay describe Detrez et al . Total anti-golimumab antibody concentration measure every venous sample . Free anti-golimumab antibody concentration measure serum golimumab concentration limit quantification venous sample DBS sample ( base adalimumab serum concentration measure laboratory , expect 11 % sample measure within first year treatment undetectable golimumab concentration ) . BASELINE CHARACTERISTICS : - Baseline characteristic include : sex , age diagnosis , weight , body mass index , disease extent , smoke status ( never , ex , active ) , primary sclerosing cholangitis , haemoglobin , serum albumin , C-reactive protein - Previous medical characteristic include previous use mesalamine , steroid , immunosuppressive agent , ciclosporin , infliximab , adalimumab , vedolizumab , … - Current medical characteristic include use mesalamine , use steroid ( dose , duration since initiation ) , use immunosuppressive agent ( dose , duration since initiation ) , use golimumab ( dose , duration since initiation , last dose ) , … QUESTIONNAIRE REGARDING PATIENT FRIENDLINESS : • At end study participant request fill questionnaire regard patient friendliness dry blood spot ( DBS ) methodology</detailed_description>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age least 18 moment inclusion Established diagnosis ulcerative colitis ( UC ) Patients golimumab therapy moderatetosevere colitis , include minimally 3 patient initiate golimumab therapy Subjects Crohn 's disease , IBD type unclassified Subjects underwent subtotal colectomy proctocolectomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>golimumab</keyword>
	<keyword>drug monitoring</keyword>
	<keyword>home base care</keyword>
</DOC>